Statins and risk of cardiovascular disease: Emulating a primary prevention trial in breast cancer survivors - PubMed
4 hours ago
- #statin therapy
- #cardiovascular disease prevention
- #breast cancer survivors
- The study aimed to estimate the effect of statin therapy versus usual care on 5-year cardiovascular disease (CVD) risk in breast cancer survivors using real-world data.
- Participants included women aged 40-84 with stage 0-III breast cancer, no prior CVD, low LDL cholesterol levels (100-160 mg/dL), and no recent statin use from 1993-2022.
- In intention-to-treat analysis, statin therapy showed no significant reduction in 5-year CVD risk compared to usual care, with a risk difference of 0.3% and risk ratio of 1.04.
- Per-protocol analysis suggested a possible reduction in CVD risk with statins (risk difference -0.9%, risk ratio 0.85), but results were imprecise and not statistically significant.
- Adherence rates were low, with 48% of statin initiators and 24% of usual care group adhering to their initial strategy at 5 years.
- The conclusions indicate that statins may reduce CVD risk in breast cancer survivors, but more research is needed on statin adherence and discontinuation in this population.